×
About 18,913 results

ALLMedicine™ Lymphomas Center

Research & Reviews  6,202 results

Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
https://doi.org/10.1073/pnas.2105898119
Proceedings of the National Academy of Sciences of the Un... Liao Y, Chen CH et. al.

Jan 16th, 2022 - Drugs that block the activity of the methyltransferase EZH2 are in clinical development for the treatment of non-Hodgkin lymphomas harboring EZH2 gain-of-function mutations that enhance its polycomb repressive function. We have previously reported...

Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.
https://doi.org/10.1007/s12149-021-01703-7
Annals of Nuclear Medicine; McKay MJ, Taubman KL et. al.

Jan 15th, 2022 - Accurate target delineation is an absolute requirement for modern radiotherapy planning. Historically, structural imaging modalities have been used for this purpose, but there is a considerable role for functional imaging with PET/CT to contribute...

Distinct clinical and genetic features of hepatitis B virus-associated follicular lymph...
https://doi.org/10.1182/bloodadvances.2021006410
Blood Advances; Ren W, Wang X et. al.

Jan 15th, 2022 - Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-cell lymphoma (DLBCL) patients from China, an endemic area of HBV infection, have chronic HBV infec...

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03809767

Jan 14th, 2022 - This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma.

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02465060

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

see more →

Guidelines  23 results

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Primary extranodal lymphoma of the glands. Literature review and options for best pract...
https://doi.org/10.1016/j.critrevonc.2019.01.005
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for ...
https://doi.org/10.1111/bjd.17240
The British Journal of Dermatology; Gilson D, Whittaker SJ et. al.

Dec 19th, 2018 - British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.|2018|Gilson D,Whittaker SJ,Child FJ,Scarisbrick JJ,Illidge TM,|methods,standards,methods,standards,therapy,t...

see more →

Drugs  273 results see all →

Clinicaltrials.gov  303 results

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03809767

Jan 14th, 2022 - This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma.

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
https://clinicaltrials.gov/ct2/show/NCT02465060

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of pa...

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02793583

Jan 13th, 2022 - The purpose of this study is to evaluate the efficacy and safety of umbralisib monotherapy and the umbralisib + ublituximab (U2) combination in aggressive and indolent lymphomas and to also explore the U2 regimen in combination with bendamustine i...

Magnetic Resonance Imaging:A Window to Anthracycline Toxicity
https://clinicaltrials.gov/ct2/show/NCT03211520

Jan 13th, 2022 - This is a pilot study with a descriptive study design. Anthracycline induced late onset cardiotoxicity, defined in terms of abnormal findings on echocardiography, has been reported to occur in 57% of childhood cancer survivors. Serial monitoring o...

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Ped...
https://clinicaltrials.gov/ct2/show/NCT03526250

Jan 12th, 2022 - PRIMARY OBJECTIVE: I. To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymph...

see more →

News  753 results

Expansion Cohort Explores Efficacy of Novel Treatment for Waldenström Macroglobulinemia
https://www.onclive.com/view/expansion-cohort-explores-efficacy-of-novel-treatment-for-waldenstr-m-macroglobulinemia

Jan 5th, 2022 - Treatment options for patients with Waldeström macroglobulinemia (WM) are often derived from those developed for patients with multiple myeloma and other low-grade lymphomas. Patients with WM are relatively rare. Their disease is defined as lympho...

Meeting the unmet need in multiple myeloma
https://www.mdedge.com/hematology-oncology/article/249921/multiple-myeloma
Walter Alexander

Dec 15th, 2021 - In multiple myeloma, survival has been very significantly improved by immunomodulatory drugs, proteasome inhibitors, and CD38-targeting antibodies. Despite these advances, multiple myeloma, which is characterized by malignant proliferation of clon.

Overview of Marginal Zone Lymphoma and Frontline Treatment
https://www.onclive.com/view/overview-of-marginal-zone-lymphoma-and-frontline-treatment

Dec 13th, 2021 - Tycel Jovelle Phillips, MD: At this point marginal zone lymphoma is very common, at least as far as indolent lymphomas that we see. The numbers aren’t nearly as high as what we see with follicular lymphoma. Marginal zone lymphoma from some reports...

Naratuximab Emtansine Plus Rituximab Serves Unmet Need in Relapsed/Refractory DLBCL Treatment
https://www.onclive.com/view/naratuximab-emtansine-plus-rituximab-serves-unmet-need-in-relapsed-refractory-dlbcl-treatment

Dec 13th, 2021 - Naratuximab emtansine plus rituximab (Rituxan) had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma (DLBCL) and other non-Hodgkin B-cell lymphomas (B-NHL), accord...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

see more →

Patient Education  11 results see all →